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Background. The role of podocytes in human crescentic
glomerulonephritis (GN) has been underestimated. This may
be due to the confounding fact that “dysregulated” podocytes
are able to proliferate, lose their markers, and acquire new
epitopes. Moreover, in experimental anti-glomerular basement
membrane (GBM) crescentic GN, podocytes participate in the
crescent formation. The aim of this study was to investigate the
involvement of podocytes in human immune crescentic GN.
Methods. Renal biopsies from 12 patients with anti-GBM dis-
ease and 14 with class IV lupus GN were studied by immuno-
histochemistry for the following markers: (1) synaptopodin,
GLEPP1, podocalyxin, podocin, a-actinin-4, and vimentin for
podocyte identification; (2) PCNA, Ki-67, and p57 for cell cy-
cle assessment; (3) cytokeratins for identifying epithelial cells
but not normal podocytes; (4) CD68 for tagging a macrophagic
epitope; (5) alpha-smooth-muscle actin (a-SMA), a phenotypic
marker of myofibroblasts.
Results. “True” (capsular) crescents lining Bowman’s capsule
and (tuft) “pseudocrescents” covering the glomerular tuft with
a persistent patent urinary space were present in the 2 types
of crescentic GN in similar percentages. Several features in-
dicated that podocytes were involved in the formation of the
both crescent types. Identifiable podocytes expressed prolifer-
ation markers. Podocyte cytoplasmic expansions and racket-
like podocytes bridged between the tuft and Bowman’s capsule.
True and pseudocrescents contained labeled podocytes. In ad-
dition, podocytes located outside of the crescents had often lost
their markers (dedifferentiation) and acquired new epitopes
(cytokeratins and CD68).
Conclusion. In human immune crescentic GN, podocytes un-
dergo proliferation and dysregulation that are indicative of a
podocytopathy. Podocytes contribute to crescent formation.
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Crescentic glomerulonephritis (GN) with a rapidly
progressive course is observed in a variety of GNs of
immune origin, in particular anti-glomerular basement
membrane (GBM) disease [1] and class IV diffuse lupus
nephritis [2].
The cellular composition of crescents has been de-
bated. In most publications, it has been considered
that crescents are composed of parietal epithelial cells
(PECs), monocyte/macrophages, and myofibroblasts [3,
4]. The cellular pattern of crescents appears to change
over the course of the disease, with PECs predominating
in crescents adjacent to an intact Bowman’s capsule [i.e.,
parietal basement membrane (PBM)]. Macrophages and
myofibroblasts are more numerous when the PBM is rup-
tured, interpreted as representing a more severe and/or
later stage of the disease [4–7]. A progression analogous
to that seen in the human disease has been observed
in experimental crescentic GN [8, 9]. A number of au-
thors have contended that podocytes do not participate
in crescent formation [7, 10, 11]. This opinion was based
on the fact that cells forming crescents do not express
podocyte markers, be it in human disease or in exper-
imental models. These markers were CD10 (CALLA)
podocalyxin, synaptopodin, glomerular epithelial protein
1 (GLEPP1), podocin, CD2-AP, nephrin, Wilm’s tumor
antigen I (WT1) [12–15]. The cyclin-dependent kinase in-
hibitors (CKIs) p27 and p57 [14, 16–18] are expressed on
normal podocytes. In glomeruli, cytokeratins (CK) iden-
tify PECs and not normal podocytes, whereas cells form-
ing crescents may express CK [19–21].
In fact, cell typing may be difficult when the disease
process alters some of the cell epitopes. For instance,
in cellular variants of focal segmental glomerulosclero-
sis (FSGS), such as collapsing GN and HIV-associated
nephropathy (HIVAN), “dysregulated” podocytes pro-
liferate [22, 23], dedifferentiate, thereby losing their nor-
mal epitopes [24–27], and transdifferentiate, acquiring
macrophagic [24, 27] or myofibroblastic epitopes [14, 28].
That podocytes participate in the formation of cres-
cents has recently been demonstrated in an experimental
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Table 1. Clinical features
Age at Number of Interval between Serum
Patient biopsy Lung previous renal clinical onset Proteinuria creatinine
cases N Gender time years involvement flares before biopsy and biopsy months g/day lmol/dL Outcome
Anti-GBM
1 M 56 + 0 10 2 106 CHD
2 M 59 0 0 <1 Anuria 100 Transpl
3 M 65 0 0 <1 Anuria 116 CHD
4 M 57 + 0 1 3.5 200 CHD
5 F 72 + 0 1.5 0.5 75 Death
6 M 22 + 0 3 10 90 Death
7 M 22 + 0 <1 5 65 CHD
8 M 75 0 0 <1 Anuria 120 CHD, death
9 F 38 0 0 2 3 15 CR
10 F 59 + 0 1 6 94 CHD
11 F 47 0 0 <1 Anuria 200 CHD, death
12 M 70 0 0 <1 4 90 CHD
Lupus
13 F 28 1 36 5 10 NA
14 F 30 0 1 6 70 CHD
15 F 29 0 14 6 10 CR
16 F 32 1 24 8 48 CHD
17 M 26 0 2 8 11 CR
18 F 38 0 11 2.3 9 CR
19 F 45 1 33 4.8 16 NA
20 F 26 0 <1 5 23 NA
21 F 25 0 26 3 16 PR
22 F 38 1 12 6 12 PR
23 F 22 1 11 5 60 CR
24 F 27 0 1 Anuria 90 Transpl
25 F 54 1 134 7.5 6 CR
26 F 31 1 84 4 7 NA
Abbreviations are: NA, non available for patients treated in their referring hospital; CHD, chronic hemodialysis; CR, complete remission; PR, partial remission;
Transpl, renal transplantation.
model of anti-GBM GN. In the early stages of the dis-
ease, before crescent formation, podocytes, which still
expressed their normal markers, were shown to form
bridges between the GBM and the PBM. The part of the
podocyte adhering to the PBM appeared to insert itself
between adjacent PECs [13]. The same podocyte bridge-
forming phenomenon was also shown in a strain of trans-
genic mice, which express b-galactosidase in podocytes
in an irreversible fashion. These b-galactosidase–positive
podocytes also form bridges between the GBM and the
PBM, proliferate, and participate in the formation of cres-
cents [15].
The purpose of this study was to show that podocytes
are dysregulated and participate in the formation of cres-
cents found in 2 forms of human GN, that is, anti-GBM
disease and class IV diffuse proliferative lupus GN.
METHODS
Patients and renal biopsies
Patient data are depicted in Table 1. At presentation,
the 12 patients with anti-GBM GN and the 14 patients
with class IV proliferative diffuse lupus GN had under-
gone a renal biopsy for rapidly progressive GN. In 1
patient, a repeat biopsy was performed 4 months after
the end of the induction treatment in order to determine
the reason for rising serum creatinine levels. The 12 pa-
tients with anti-GBM disease had both a linear fixation
of IgG along the GBM and circulating anti-GBM anti-
bodies. Moreover, 7 patients presented with pulmonary
involvement. The 14 patients with class IV proliferative
diffuse lupus GN fulfilled criteria for the diagnosis of sys-
temic lupus erythematosus as defined by the American
Rheumatism Association. All had positive anti-double-
stranded DNA antibodies.
The 27 renal biopsies were fixed in alcoholic Bouin’s
solution and embedded in paraffin for histology and
immunohistochemistry, and other biopsy material was
frozen for immunofluorescence. The number of glomeruli
per biopsy was 20.3 ± 4.1 (mean ± SEM) and 16.2 ± 2.4 in
anti-GBM GN cases and in class IV proliferative diffuse
lupus GN cases, respectively.
Crescents were defined as cellular structures made of 3
or more cell layers in the urinary space. “True” (i.e. capsu-
lar) crescents were distinguished from tuft or “pseudocre-
scents” [29, 30]. In true crescents, the simple epithelium
of Bowman’s capsule is replaced by several cell layers
and the urinary space is often obliterated, either seg-
mentally or circumferentially by these proliferating cells.
Pseudocrescents, recognizable in glomeruli where there
remains some free urinary space, are formed of cells
proliferating close to the glomerular tuft and not lining
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Bowman’s capsule. True crescents and pseudocrescents
may coexist in the same glomerulus. The number of true
crescents and pseudocrescents was counted in all biop-
sies only in glomeruli presenting cellular and fibrocellu-
lar crescents. Fibrous crescents and obsolescent glomeruli
were excluded from counting because the distinction be-
tween true and pseudocrescents was often impossible in
these stages of lesion.
Controls
Controls consisted of normal portions of 6 kidneys
removed for renal carcinoma in patients with no pro-
teinuria and of renal biopsies from 5 nephrotic patients
with minimal change disease. For immunohistochemical
assessment of these control renal tissues, attention was
paid to the characterization of the podocytes covering
the tuft (visceral podocytes) and of the so-called parietal
podocytes [31] along the PBM and the tuft-to-capsule
podocyte bridges [32].
Immunohistochemistry markers
Cytokeratin (CK) polypeptides were labeled using
C2562 monoclonal antibody (mAb) cocktail (Sigma
Aldrich Chimie, St. Quentin Fallavier, France) directed
against 9 CK types and used as a PEC marker [33]. Nor-
mal podocytes are not labeled by this mAb. Vimentin,
labeled by V9 mAb (Dako, Trappes, France), was used
as a mesenchymal marker that is also normally pos-
itive on podocytes and very rarely on normal PECs.
Macrophagic epitope CD68 was identified using PGM1
mAb (Dako) [24, 27]. Podocytes were characterized us-
ing an anti-human podocalyxin mAb (MLC48A8, a gift
of Pierre Ronco, M.D., INSERM U489, Hoˆpital Tenon,
Paris, France), an anti-synaptopodin mAb, clone G1D4
(Progen and Biotechnik, Heidelberg, Germany), an anti-
GLEPP-1 mAb, clone 5 C11 (Biogenex, San Ramon, CA,
USA), an anti-human podocin rabbit polyclonal antibody
(pAb), (a gift of M.C. Gubler, M.D., INSERM U 574,
Hoˆpital Necker, Paris, France), and an anti-human a–
actinin-4 pAb (ImmunoGlobe, Himmelstadt, Germany).
The CKI p57 [17, 18] was identified using a rabbit pAb
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). An
anti-PCNA mAb, clone PC10 (Dako), was used to tag
proliferating cell nuclear antigen (PCNA). An anti-Ki-
67 mAb (Dako) was also used to detect proliferating
cells. Anti-WT1 C19 pAb (Santa Cruz Biotechnology)
and anti-nephrin N-20 pAb (Santa Cruz Biotechnology)
were attempted, but could not be made to work on Bouin-
fixed material. Alpha-smooth-muscle actin (a-SMA) was
labeled using mAb 1A4 (Neomarkers, Union City, CA,
USA), a phenotypic marker of myofibroblasts [14]. Anti-
gen retrieval, visualization systems, and negative proce-
dures were performed as previously described [27].
Cell counts
For each renal biopsy, 2 independent observers as-
sessed all the glomerular sections for all the immuno-
histochemical markers. Regarding crescents, the per-
centage of cells positive for synaptopodin, GLEPP-1,
podocin, podocalyxin, a-actinin-4, CK, CD68, vimentin,
and PCNA was counted in each glomerulus according to
the type of crescent. In the analysis of the cell types form-
ing crescents, only cellular and fibrocellular crescents
were studied, excluding fibrous crescents as indicated
above. PCNA as a proliferation marker was selected for
counting because it gave more homogeneous labeling
than Ki67. The percentage of unlabeled crescent cells was
calculated as follows: 100% minus the percentage of the
CK, CD68, and synaptopodin labeled cells.
Statistics
One the one hand, the distribution of the crescent types
was compared between both types of GN. On the other
hand, the distribution of the immunolabeled cells was
compared according to the crescent types and to the GN
types. Chi-square tests and t tests were used as appropri-
ate, with P values < 0.05 considered significant.
RESULTS
Standard pathology
By light microscopy, the cells within true crescents were
cuboidal or spindle-shaped and often formed pseudo-
tubules. The cells of the pseudocrescents (Fig. 1) did not
assume a spindle-shaped appearance and, unlike those
of true crescents, were not surrounded by extracellular
matrix. They had a rounded, hyperplastic, and hyper-
trophic appearance, and frequently contained vacuoles
and numerous hyaline droplets. They were sometimes
multinucleated or showed mitotic figures. The cells of
the pseudocrescents were either adherent to the GBM
or detached and drifting free in the urinary chamber.
Some cells were racket-shaped, with a narrow portion
attached to the GBM and a larger portion containing the
nucleus projecting into urinary space (Fig. 1). True and
pseudocrescents coexisted within the same biopsy (Fig. 2)
in all the cases. The appearance of some glomeruli was
analogous to that seen in collapsing GN. Giant cells were
sometimes seen adherent to the GBM (Fig. 3). In both
types of GN, the glomerular tuft showed endocapillary
proliferation with an infiltrate of monocytes and poly-
morphonuclear leukocytes and areas of necrosis. The ap-
pearance of the glomeruli was quite heterogeneous from
one biopsy to another and even within a given biopsy. The
results were similar in the 2 types of immune crescentic
GN studied. The percentages of true crescents vs. pseu-
docrescents were not significantly different: 52.9 ± 6.9%
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Table 2. Distribution of crescent cell labelling on the biopsies between GN types and crescent types
Anti-GBM GN Class IV lupus GN
(N = 13 biopsies) (N = 14 biopsies)
True crescents Pseudocrescents True crescents Pseudocrescents
Synaptopodin-positive cells 2.3 ± 0.7a,b (0–5) 10.1 ± 3.1 (1.7–40) 7.3 ± 2.1a (0.8–22.5) 11.0 ± 3.5 (0–40)
GLEPP1-positive cells 1.3 ± 0.7a,b (0–7.3) 5.1 ± 2.0b (0–20) 6.9 ± 2.1a (0–4.7) 17.6 ± 8.3 (0–41.5)
Podocin-positive cells 2.5 ± 0.8a (0.5–8.2) 15.8 ± 2.4 (3.2–25) 2.8 ± 0.7a (1.3–8) 19.3 ± 7.9 (4–73)
Podocalyxin-positive cells 5.4 ± 1.5 (0–16) 8.7 ± 2.3 (3–27.5) 4.6 ± 0.9a (2–10) 10.2 ± 1.6 (6–18.8)
a-actinin4–positive cells 18.3 ± 5.9 (4.6–58.3) 23.4 ± 5.0 (6.2–40) 11.2 ± 3.7a (3–20) 33.2 ± 5.6 (11.6–66)
CK-negative cells 52.5 ± 6.4 (0–82.6) 49.1 ± 6.7 (0–78.7) 56.6 ± 7.9 (6.8–99.2) 64.5 ± 8.3 (6.7–96.6)
CK-positive cells 29.2 ± 3.3a,b (1.4–70.0) 42.9 ± 7.1b (1.5–78.9) 17.0 ± 7.7 (0–91.1) 22.3 ± 8.5 (0–93.3)
CD68-positive cells 24.6 ± 8.3b (3.1–60.0) 19.5 ± 6.0b (2.4–69.3) 9.3 ± 3.7 (0–36.0) 3.0 ± 1.8 (0–21.2)
Vimentin-positive cells 89.5 ± 6.6 (55.0–100) 68.3 ± 9.3 (39.5–100) 80.6 ± 8.4 (15.1–100) 69.0 ± 9.8 (9.5–100)
PCNA-positive cells 7.7 ± 3.4 (0.5–40) 14.9 ± 5.1 (0.3–50.0) 14.4 ± 5.5 (0.8–57.0) 16.0 ± 5.1 (0.5–50)
Abbreviations are: CK, cytokeratin; GBM, glomerular basement membrane; GN, glomerulonephritis. Mean ± SEM (range of percentages of labelled crescent cells
per glomerulus).
aP < 0.05 true vs. pseudocrescents; bP < 0.05 anti-GBM GN vs. class IV lupus GN.
vs. 47.1 ± 6.9% and 57.1 ± 6.2% vs. 42.9 ± 6.2% in anti-
GBM disease and type IV lupus GN, respectively. Thus,
pseudocrescents accounted for nearly half of crescents.
Immunofluorescence in anti-GBM disease was charac-
teristic with a linear fixation of immunoglobulin G (IgG)
along the GBM, a glomerular granular fixation of C3, and
the presence of fibrinogen in the urinary space. In type IV
lupus GN, the immune deposits contained predominantly
polyclonal IgG, C3 and, in most instances, C1q, with vari-
able deposits of IgA and IgM and often fibrinogen in the
urinary space.
Phenotypes of the glomerular cells
Controls
In the glomeruli, all the podocyte markers labeled all
visceral podocytes and some parietal podocytes. Pari-
etal podocytes (Fig. 4) were detected in a majority of
Bowman’s capsules at their vascular pole in continuity
with the visceral podocytes. Rare bridges between vis-
ceral podocytes and Bowman’s capsule (Figs. 5 and 6)
were observed, usually close to the vascular hilum of the
glomerulus. CKI p57 tagged all nuclei of podocytes and
the nuclei of very rare PECs. Vimentin marked all the
podocytes, but only rare cells lining the PBM. PCNA and
Ki-67 were detected on rare PECs, but not on visceral
podocytes. Anti-CK C2562 mAb tagged numerous PECs,
but no podocytes.
Crescentic GN
Podocyte labeling
Podocyte markers used (synaptopodin, GLEPP1,
podocin, podocalyxin, and a–actinin-4) yielded similar
informations (Table 2). Podocytes, in areas of glomeruli
not involved in crescent formation, most frequently main-
tained their expression of podocyte markers, but some-
times showed loss of these markers. For the most part, the
cells of the true and pseudocrescents were not marked,
but were admixed with numerous labeled cell fragments
and occasional labeled intact cells (Figs. 7 to 9). Labeled
cells accounted for low percentage of crescent cells. How-
ever, their density was quite heterogeneous from one
crescent to another. Using serial sections, we have been
able to colocalize several of the podocyte markers used.
For all the podocyte markers, the percentage of labeled
cells was higher in pseudocrescents than in true crescents.
For podocin, podocalyxin, and a–actinin-4, the percent-
age of labeled cells in true and pseudocrescents was not
different between the GN types. For synaptopodin, the
percentage of labeled cells in true crescents was higher in
lupus GN than in anti-GBM disease cases. For GLEPP-1,
the percentage of labeled cells in true and pseudocres-
cents was higher in lupus GN than in anti-GBM disease
cases. More cells were marked with anti-a–actinin-4 than
with any other podocyte marker.
Several features indicated that podocytes were in-
volved in the formation of true and pseudocrescents
(Figs. 7 to 9). Labeled podocytes were found in both types
of crescents. Finger-like cytoplasmic expansions positive
for podocyte markers protruded within the urinary space
(Fig. 10A). In addition, labeled podocytes still in place
changed their shape and acquired a racket-like appear-
ance (Fig. 10B) in which the large portion containing the
nucleus bulged into the urinary space. Outside the cres-
cents, cytoplasmic expansions and racket-like podocytes
occasionally formed bridges between the GBM and the
PBM (Figs. 11 and 12). They sometimes were in contact
with the PBM between 2 adjacent PECs (Fig. 13). The
bridging podocytes were observed in 13.7% ± 2.7 of the
glomeruli in lupus GN cases and in 5.3% ± 1.3 of the
glomeruli in the anti-GBM disease cases. Podocyte cyto-
plasmic expansions and whole podocytes still expressing
their markers were observed on the inner aspect of the
PBM and in the outer portion of true crescents. They were
separated from the tuft by the urinary space without any
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contiguity with the underlying GBM (Fig. 14). Some had
an elongated cell body and a flat nucleus. More rarely,
they were in continuity with lobule adhesions to the PBM
(Fig. 15), with adhesions of the podocyte expansions to
the PBM, and with racket-like podocyte adhesions to
the PBM. Occasional podocytes were localized between
bands of the split PBM or passed through breaks of the
PBM (Figs. 11 and 12). Rounded labeled podocytes de-
tached from the GBM and appearing viable were ob-
served in the urinary space (Fig. 16) and in the tubular
lumens. Some of these detached podocytes were adher-
ent to the PEC or to the PBM (Figs. 17 and 18). Labeled
podocytes were identified in fibrous crescents and in oc-
casional obsolescent glomeruli (Fig. 19).
Vimentin labeling
In the glomeruli, the majority of cells within true and
pseudocrescents were vimentin positive, with no differ-
ence between crescent types or GN types. In addition to
crescents, cells floating in the urinary space and in the
lumen of tubules, PECs and racket-like podocytes ex-
pressed vimentin. Podocyte expansions bridging between
the GBM and the PBM (Fig. 20) and podocytes bulging
into the urinary space were also vimentin-positive, as
were giant cells attached to the GBM.
Cytokeratin labeling
In true crescents, the cuboidal cells assuming an ep-
ithelial appearance were organized in layers or in pseu-
dotubules. They were occasionally CK-positive, but much
more frequently CK-negative. These apparently epithe-
lial, although CK-negative cells were often the most
abundant components in true crescents (Fig. 21). The
percentage of CK-negative cells was not significantly dif-
ferent between crescent types or GN types. On serial
sections using other labeling, CK-negative cells did not
express any other markers except vimentin. CK labeling
could infrequently be found on individual still-attached
podocytes that were not located in crescents. Moreover,
CK-positive rows of podocytes could be observed oppo-
site to CK-negative PECs (Fig. 22).
Macrophagic epitope labeling
In the crescents, CD68-positive cells were less numer-
ous than CK-positive and CK-negative cells. The per-
centage of CD68-positive cells was higher in anti-GBM
disease crescents than in lupus crescents. Some cells ad-
herent to the PBM in a PEC location and some cells
adherent to the GBM in a podocyte location were CD68-
positive. That latter labeling pattern was particularly
observed in glomeruli exhibiting an appearance of col-
lapsing GN (Fig. 23). Giant cells attached to the GBM
(Fig. 24) and large round cells floating in the urinary space
around some collapsed glomerular tufts and in the tubu-
lar lumens were CD68-positive.
Cyclin-dependent kinase inhibitor p 57 labeling
None of the cell nuclei in the true and pseudocrescents
expressed CKI p57 (Fig. 25). Among the podocytes cov-
ering lobules without crescents, some podocytes had lost
the expression of p57, a feature contrasting with adja-
cent p57-positive podocytes (Fig. 26). The nuclei of the
racket-like podocytes adherent to the PBM were incon-
stantly labeled.
PCNA and Ki67 labeling
In true crescents, a high percentage of cells were PCNA
or Ki-67 positive. PCNA and Ki-67 were also expressed in
numerous PECs outside the crescents. In addition, clearly
identifiable podocytes within pseudocrescents (Fig. 27) or
outside crescents were positive. Using double labeling,
some podocytes coexpressed synaptopodin and PCNA
(Fig. 28). The proliferation rate was not different between
the crescent or GN types.
Alpha-SMA labeling
In pseudocrescents, no cells express a-SMA. In true
crescents, a-SMA–positive cells were scarce in cellular
crescents (ranging from 0% to 5% in all the biopsies).
But they represent an important cell component in fi-
brocellular true crescents (ranging from 5% to 30%),
where these cells had a spindle-shaped appearance and
were situated between layers of epithelial cells or around
pseudotubules. Furthermore, in serial sections podocyte-
marker-positive cells in pseudo and true crescents did not
express a-SMA. In all the glomeruli, the mesangial cells
were strongly labeled.
DISCUSSION
The origin of cells forming glomerular crescents is con-
troversial. It has generally been considered that epithe-
lial cells of the crescents found in human GN derive from
PECs and not from podocytes. This opinion was based on
the absence of podocyte markers identifiable in crescent
cells, be it in man or in experimental models [5, 10–14].
Nonetheless, the fact that cells composing crescents do
not express podocyte markers does not rule out the possi-
bility that a portion, perhaps quite significant, of crescen-
tic cells might be of podocyte origin. In man, podocytes
can proliferate [22, 23], “dysregulate,” and lose their char-
acteristic epitopes. This has been observed in the cellular
forms of FSGS, collapsing GN, and HIVAN [24–27].
Dysregulated podocytes are capable to proliferate
in human immune crescentic GN
Podocytes, clearly identifiable by their adhesion to the
GBM and detected outside the crescents, are modified
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Fig. 1–14.
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and able to proliferate. They express the proliferation
markers PCNA and Ki-67 and lose the expression of
CKI p57, which inhibits entry of normal podocytes into
the cell cycle [17, 18, 26]. In addition, some podocytes
coexpressed podocyte (synaptopodin) and proliferation
(PCNA) markers, suggesting that proliferative podocytes
actually contribute to the crescent formation.
Podocytes participate in crescent formation in human
immune crescentic GN
Contrary to previous reports, the podocyte markers
used in this study (synaptopodin, GLEPP1, podocalyxin,
podocin, and a-actinin-4) indicate that podocytes are in-
deed involved in human crescentic GN. The fact that
a-actinin-4 labeling constantly gave higher percentages
of positive cells than the other podocyte markers might
be related to the implication of a-actinin-4 in cell motil-
ity [34]. Therefore, a-actinin-4, a marker of podocytes in
normal glomeruli, could exhibit a more widespread ex-
pression in diseased kidney. Our results are consistent
with the fact that podocytes: (1) are damaged outside of
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Fig. 1. Pseudocrescent characterized by a proliferation of hypertrophic cells (arrows) close to the tuft, not lining the Bowman’s capsule so that the
urinary space is still patent. Some proliferated cells still adherent to the glomerular basement membrane (GBM) have a racket-like appearance
(double arrow). It is associated with cells floating in the urinary space (arrowheads). Anti-GBM disease patient 8. Masson’s trichrome ×450.
Fig. 2. True (∗) and pseudocrescents (arrows) coexist within the same biopsy from anti-GBM disease patient 2. Masson’s trichrome ×150.
Fig. 3. Giant vacuolated cells are adherent to the GBM. Anti-GBM disease patient 3. Masson’s trichrome ×400.
Fig. 4. Parietal podocytes (arrows) lining the parietal basement membrane (PBM). Note the usual pattern in which the parietal epithelial cell
(arrowhead) is covering the edge of the adjacent parietal podocyte. Normal control kidney. Synaptopodin immunolabeling ×350.
Fig. 5. Visceral podocyte cytoplasmic expansion (arrow) bridging with the Bowman’s capsule at the vascular pole of a glomerulus in a control
normal kidney. Podocin immunolabeling. ×350.
Fig. 6. Racket-like visceral podocyte forming a bridge (arrow) with the Bowman’s capsule in a control normal kidney. Podocin immunolabeling
×550.
Fig. 7. Synaptopodin-labeled nucleated cell (arrow) in a true crescent on a biopsy from anti-GBM disease patient 5. It is associated with numerous
labeled cell fragments (arrowheads). ×350.
Fig. 8. Numerous synaptopodin-labeled nucleated cells (arrows) in a pseudocrescent on a biopsy from class IV lupus GN patient 13. ×400.
Fig. 9. Numerous a–actinin-4–labeled nucleated cells in a pseudocrescent (arrow) on a biopsy from class IV lupus GN patient 16. ×500.
Fig. 10. (A) Labeled finger-like cytoplasmic expansion (arrowhead) of a visceral podocyte protruding in the urinary space. Class IV lupus GN
patient 18. GLEPP1 immunolabeling. ×500. (B) Labeled racket-like visceral podocyte (arrowhead) still adhering to the glomerular tuft and budging
in the urinary space. It is adjacent to a pseudocrescent (arrow). Anti-GBM disease patient 4. Podocin immunolabeling. ×450.
Fig. 11. Podocalyxin-labeling of podocytes (arrowheads) passed through a break of the Bowman’s capsule on a biopsy from class IV lupus GN
patient 16. Note a bridge (arrow) between the glomerular tuft and the Bowman’s capsule. ×300.
Fig. 12. Silver staining showing the break (arrowheads) of the PBM through which the podocytes passed outside of Bowman’s capsule in the same
glomerulus as in Figure 11. Note a bridge (arrow) between the glomerular tuft and the Bowman’s capsule. ×300.
Fig. 13. Labeled podocyte in contact with the parietal basement membrane (arrow) between two adjacent parietal epithelial cells (arrowheads).
Note that podocalyxin also labels endothelial cells in an endocapillary location. Class IV lupus GN patient 25. Podocalyxin immunolabeling. ×700.
Fig. 14. Labeled crescent cells (arrows) in the outer part of a true crescent and localized between the bands of the split PBM. Some are elongated
cells. Class IV lupus GN 26. Synaptopodin immunolabeling combined with PAS staining. ×400.
crescents in a pattern consistent with a podocytopathy
[35]; (2) do participate in the formation of pseudo- and
true crescents. The fact that the loss of podocyte mark-
ers is so widespread suggests that the marker-retaining
podocytes we have identified here, in fact, only repre-
sent a minimal estimate of the total participation of dys-
regulated podocytes in crescent formation. Thus, outside
true crescents, podocyte changes were analogous to those
seen in the cellular forms of FSGS and in collapsing GN
[29, 30]. Dysregulated proliferating podocytes are also
observed in Denys-Drash syndrome [36]. In our cases,
the hypertrophic and hyperplastic podocytes, attached to
the GBM and not to the PBM, were composed of large
rounded, loosely cohesive cells, often detached and seen
in the urinary space and in the tubular lumens. They
were sometimes multinucleated or vacuolized [29, 30].
These large hyperplastic cells could form pseudocres-
cents characterized by a persistent urinary space and a
clear-cut separation from Bowman’s capsule. Although
most of the cells of the pseudocrescents were negative
for the podocyte markers used, a number of nucleated,
therefore viable, cells were clearly labeled, indicating
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Fig. 15–28.
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that they were podocytes. Our study also provides evi-
dence that podocytes contribute to the formation of true
crescents. Cells labeled with the podocyte markers were
found among the crescent cell population, particularly
cells lining the inner aspect of the PBM, or situated be-
tween strands of the PBM or having passed through PBM
breaks to the outside of the Bowman’s capsule. Most
often, these labeled cells in true crescents were with-
out any continuity with the underlying GBM, suggesting
that these podocytes were not subsumed in the crescent
by physical contiguity. Podocyte cytoplasmic expansions,
as well as protruding racket-like podocytes, frequently
formed bridges between the GBM and Bowman’s cap-
sule. These data suggest that podocytes detected in the
crescents derive from visceral podocytes through a pro-
cess of podocyte bridging, as described in experimental
murine models [15].
Podocytes also participate in crescent formation
in animal models
Our results are substantiated by those found in mouse
models of crescentic anti-GBM GN. Le Hir et al [13] have
shown that in the initial phases of GN, before the for-
mation of crescents, podocytes expressing their specific
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 15. Some labeled crescent cells (arrowheads) are in continuity with lobule or podocyte expansion adhesions to the PBM (arrows) on a biopsy
from class IV lupus GN patient 26. Synaptopodin immunolabeling combined with PAS staining. ×450.
Fig. 16. Labeled rounded podocytes (arrows) detached from the GBM are floating in the urinary space. Class IV lupus GN 21. Synaptopodin
immunolabeling. ×350.
Fig. 17. Labeled detached podocyte (arrow) adherent to parietal epithelial cells. Class IV lupus GN 17. Synaptopodin immunolabeling. ×900.
Fig. 18. Labeled detached podocyte (arrow) adherent to the parietal basement membrane. Class IV lupus GN 23. Podocin immunolabeling. ×900.
Fig. 19. Labeled cells and cell remnants are still observed in a fibrous crescent (arrows) adjacent to a persistent tuft (star). Anti-GBM disease
patient 10. Podocalyxin immunolabeling. ×350.
Fig. 20. Bridge (arrow) between the hyperplastic podocytes and the Bowman’s capsule. Anti-GBM disease patient 6. Vimentin immunolabeling.
×800.
Fig. 21. No crescent cell expresses cytokeratins in this true crescent (stars). Anti-GBM disease patient 11. Cytokeratin immunolabeling. ×350.
Fig. 22. Cytokeratin-positive row of hyperplastic podocytes (arrows) opposite to cytokeratin-negative parietal epithelial cells (arrowheads). Anti-
GBM disease patient 12. ×300.
Fig. 23. Numerous CD68-positive hyperplastic dysregulated podocytes (arrows) in a glomerulus showing a pattern of collapsing GN. In addition,
CD68-positive cells are floating in the urinary space (arrowheads) and the tubular lumen (small arrow). Anti-GBM disease patient 1. ×300.
Fig. 24. Giant cell attached to the GBM is positive for CD68 (arrow). Anti-GBM disease patient 9. ×30.
Fig. 25. p57 is not expressed in the cell nuclei of a pseudocrescent (arrow). Class IV lupus GN patient 19. ×150.
Fig. 26. In some lobules without crescents, podocytes have lost the p57 expression (arrows), whereas it perisists in other normal podocytes
(arrowheads). Class IV lupus GN patient 22. ×300.
Fig. 27. In this pseudocrescent, podocytes (arrow) expressed the proliferation marker Ki-67. Class IV lupus GN patient 24. ×550.
Fig. 28. Some pseudocrescent cells coexpress the nucleus proliferation marker PCNA in red (arrows) and the membrane podocyte marker synap-
topodin in brown (arrowheads). Class IV lupus GN patient 14. ×700.
markers form bridges between the GBM and the PBM
to which they adhere. Moeller et al [15] have used trans-
genic 2.5P-Cre/ROSA26 mice whose podocytes express
b-galactosidase in an exclusive and definitive fashion.
In that model, b-galactosidase–positive cells, therefore
identifiable as podocytes, adhered to the PBM and in-
vaded the crescents in the earliest stages of their for-
mation. These b-galactosidase–positive cells, localized on
the inner aspect of the PBM and in the outer part of the
cellular crescents, expressed the proliferation marker Ki-
67, but contrary to our results in man, did not express
specific genuine podocyte markers.
Parietal podocytes may participate in crescent formation
In experimental anti-GBM crescentic GN, no parietal
podocytes are to be seen in mouse glomeruli [13]. How-
ever, in human glomeruli, parietal podocytes do exist.
The presence of parietal podocytes in the human normal
kidney has been completely overlooked, despite Gibson
et al’s publication in 1992 [31], which elegantly demon-
strated this finding by scanning and transmission electron
microscopy. These parietal podocytes covered a signifi-
cant part of Bowman’s capsule, usually in continuity with
visceral podocytes. They were centered on the vascular
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pole. Podocyte processes bridged across the urinary space
from both visceral and parietal podocytes. Occasionally,
podocyte cell bodies also formed a bridge between the
capillary tuft and Bowman’s capsule, sending processes
and pedicles to both. These morphologic observations by
electron microscopy are corroborated by our own find-
ings on immunohistochemistry analysis of normal control
kidneys. We found the same elongated podocytes along
the PBM, and the same bridging process between the
glomerular tuft and Bowman’s capsule. The notion that a
podocyte cell population is common to both the glomeru-
lar tuft and Bowman’s capsule cell lining is of great in-
terest in the discussion of crescent formation. Podocytes,
including a subset pertaining to the tuft and possibly a
subset pertaining to Bowman’s capsule lining, both able
of bridging between the tuft and the capsule, can prolif-
erate and contribute to crescent formation.
Podocytes within crescents express macrophagic markers
Cells in a visceral podocyte location, exhibiting occa-
sionally a giant cell pattern, acquire CD68 macrophagic
epitope as described in collapsing GN [24] or in cellular
forms of FSGS [27]. That podocytes proliferate, dedif-
ferentiate, and acquire macrophagic epitopes is indica-
tive of a podocytopathy [35]. That podocytes express
macrophagic features has been amply demonstrated in
an isolated glomerulus rat model [37].
Normal and dysregulated podocytes
do not express a-SMA
Given the negativity for a-SMA of podocytes in
pseudo and true crescents, podocytopathy does not ap-
pear to be associated with myofibroblastic transforma-
tion of podocytes in immune crescentic GN. Rather, these
myofbroblasts appear to be derived from cytokeratin-
positive cells [14]. A possibility that cannot be completely
ruled out with present techniques is that some of these
cytokeratin-positive cells might once have been derived
from podocytes, but no cells simultaneously expressing
podocyte markers and a-SMA were identified.
CONCLUSION
We have shown that in 2 variants of crescentic GN,
podocytes are involved in crescent formation. They fol-
low the same dysregulated pattern as that observed in the
pseudocrescents found in cellular forms of FSGS, such as
HIVAN and collapsing glomerulopathy. In all those sit-
uations, this dysregulation leads to similar morphologic
changes, such as hypertrophy, hyperplasia, proliferation,
dedifferentiation, and acquisition of new epitopes (CD68,
CK). This dysregulation is indicative of a podocytopathy.
Some podocytes composing true crescents still express
their specific markers. Bridges linking the GBM and the
PBM suggest that both visceral and parietal podocytes
contribute to crescent formation. The implications of
podocyte involvement in the subsequent progression of
crescentic GN to fibrosis and glomerular obsolescence
remain to be determined.
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